A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

NCT05683171 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Rituximab
DRUG: Lenalidomide
DRUG: Valemetostat

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]